Skip to main content

PIK3CA

Videos

Anna Martling, MD, Karolinska Institutet
Videos
01/28/2025
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD,...
01/28/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/02/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of...
01/02/2025
Oncology
Alberto Montero, MD, UH Seidman Cancer Center
Videos
10/17/2024
Alberto Montero, MD
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses...
10/17/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/24/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD,...
09/24/2024
Oncology
Heather McArthur, MD
Videos
09/16/2024
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses...
09/16/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/03/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD,...
09/03/2024
Oncology
Catherine Diefenbach, MD
Videos
10/15/2026
Catherine Diefenbach, MD
Catherine Diefenbach, MD, discusses evolving first-line treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...
Catherine Diefenbach, MD, discusses evolving first-line treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...
Catherine Diefenbach, MD,...
10/15/2026
Oncology
Marc Braunstein, MD, PhD
Videos
10/15/2026
Marc Braunstein, MD, PhD
Marc Braunstein, MD, PhD, discusses advances in CAR T-cell therapy for patients with relapsed or refractory multiple myeloma, highlighting long-term treatment-free remissions, emerging BCMA-directed therapies such as anitocabtagene...
Marc Braunstein, MD, PhD, discusses advances in CAR T-cell therapy for patients with relapsed or refractory multiple myeloma, highlighting long-term treatment-free remissions, emerging BCMA-directed therapies such as anitocabtagene...
Marc Braunstein, MD, PhD,...
10/15/2026
Oncology
Francesco Maura, MD
Videos
10/15/2026
Francesco Maura, MD
Francesco Maura, MD, discusses the evolving role of whole-genome sequencing in multiple myeloma precursor conditions, highlighting how genomic classification may distinguish malignant transformation from non-malignant disease, improve...
Francesco Maura, MD, discusses the evolving role of whole-genome sequencing in multiple myeloma precursor conditions, highlighting how genomic classification may distinguish malignant transformation from non-malignant disease, improve...
Francesco Maura, MD, discusses...
10/15/2026
Oncology
Videos
10/15/2026
Seth Wander MD, PhD; VK Gadi, MD, PhD; Paolo Tarantino, MD, PhD
In the final round, panelists consider how route of administration and patient preference affect treatment selection. They weigh the potential benefits of IV therapy—including more frequent clinical contact, closer toxicity monitoring, and...
In the final round, panelists consider how route of administration and patient preference affect treatment selection. They weigh the potential benefits of IV therapy—including more frequent clinical contact, closer toxicity monitoring, and...
In the final round, panelists...
10/15/2026
Oncology
Videos
10/15/2026
Seth Wander MD, PhD; VK Gadi, MD, PhD; Paolo Tarantino, MD, PhD
The discussion turns to how broadly and intensely to inhibit the PI3K/AKT/mTOR pathway after CDK4/6 inhibitor progression. Panelists debate whether broad, multi-node PAM inhibition should be prioritized regardless of PIK3CA status, weighing...
The discussion turns to how broadly and intensely to inhibit the PI3K/AKT/mTOR pathway after CDK4/6 inhibitor progression. Panelists debate whether broad, multi-node PAM inhibition should be prioritized regardless of PIK3CA status, weighing...
The discussion turns to how...
10/15/2026
Oncology
Videos
10/15/2026
Seth Wander MD, PhD; VK Gadi, MD, PhD; Paolo Tarantino, MD, PhD
The debate opens with a patient with PIK3CA wild-type disease progressing on an aromatase inhibitor plus a CDK4/6 inhibitor. The panelists debate whether a newly identified actionable mutation should direct the next treatment or instead...
The debate opens with a patient with PIK3CA wild-type disease progressing on an aromatase inhibitor plus a CDK4/6 inhibitor. The panelists debate whether a newly identified actionable mutation should direct the next treatment or instead...
The debate opens with a patient...
10/15/2026
Oncology
Olatunji Alese, MD, and Efrat Dotan, MD
Videos
10/14/2026
Olatunji Alese, MD; Efrat Dotan, MD
Olatunji Alese, MD, and Efrat Dotan, MD, discuss the emerging role of RAS inhibitors in pancreatic cancer, weighing significant efficacy advances against questions surrounding real-world patient selection, resistance, long-term outcomes,...
Olatunji Alese, MD, and Efrat Dotan, MD, discuss the emerging role of RAS inhibitors in pancreatic cancer, weighing significant efficacy advances against questions surrounding real-world patient selection, resistance, long-term outcomes,...
Olatunji Alese, MD, and Efrat...
10/14/2026
Oncology
Stephanie Berg, DO
Videos
10/14/2026
Stephanie Berg, DO
Stephanie Berg, DO, discusses first-line treatment selection for patients with metastatic clear cell renal cell carcinoma, highlighting the trade-offs between dual immunotherapy and immunotherapy plus tyrosine kinase inhibitor combinations,...
Stephanie Berg, DO, discusses first-line treatment selection for patients with metastatic clear cell renal cell carcinoma, highlighting the trade-offs between dual immunotherapy and immunotherapy plus tyrosine kinase inhibitor combinations,...
Stephanie Berg, DO, discusses...
10/14/2026
Oncology
Gail Roboz, MD
Videos
10/14/2026
Gail Roboz, MD
Gail Roboz, MD, discusses results from the phase 1/2 ASCERTAIN-V trial evaluating all-oral decitabine and cedazuridine plus venetoclax in patients with acute myeloid leukemia ineligible for intensive chemotherapy, highlighting encouraging...
Gail Roboz, MD, discusses results from the phase 1/2 ASCERTAIN-V trial evaluating all-oral decitabine and cedazuridine plus venetoclax in patients with acute myeloid leukemia ineligible for intensive chemotherapy, highlighting encouraging...
Gail Roboz, MD, discusses...
10/14/2026
Oncology
OLN

PIK3CA

ALIASES

Phosphatidylinositol 3-kinase catalytic subunit

References

PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) is an oncogene that encodes one piece (a subunit) of an enzyme called phosphatidylinositol 3-kinase (PI3-Kinase).1 PIK3CA plays a role in the control of cell growth, cell survival, and cell migration. Mutations in the PIK3CA gene can lead to uncontrolled cell growth and contribute to the proliferation and progression of cancer.2 

The PI3-Kinase pathway is one of many signaling pathways that are important for cell growth, transformation, adhesion, apoptosis, survival and invasion.3 PI3-Kinases are heterodimeric lipid kinases composed of catalytic and adaptor/regulatory subunits encoded by separate genes and alternative splicing. In the case of oncogenes, including PIK3CA, genetic changes such as a mutation can result in a cellular state whereby the PIK3CA gene product is constantly activated. Ultimately, this contributes toward uncontrolled cellular growth and other features that are the hallmarks of cancer.1

Gene amplifications, deletions and more recently, somatic missense mutations in the PIK3CA gene have been reported in many human cancer types including cancers of the colon, breast, brain, liver, stomach and lung. These somatic missense mutations were proposed to increase the kinase activity of PIK3CA contributing to cellular transformation.3

PIK3CA mutations are found in 20% to 25% of colon cancers and 10% of rectal cancers. In addition to colorectal cancer, PIK3CA oncogene mutations are involved in several human cancers including breast cancer, ovarian cancer, and non-small cell lung cancer (NSCLC).2

Understanding the Role of PIK3CA

News

Conference Coverage
12/03/2024
Allison Casey
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study,...
12/03/2024
Oncology
Conference Coverage
12/03/2024
Allison Casey
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial,...
12/03/2024
Oncology
News
11/05/2024
Allison Casey
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center...
11/05/2024
Oncology
News
10/31/2024
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS...
10/31/2024
Oncology
FDA Approval
10/10/2024
Allison Casey
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib,...
10/10/2024
Oncology
News
10/02/2024
Allison Casey
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial...
10/02/2024
Oncology
News
09/24/2024
Allison Casey
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is...
09/24/2024
Oncology
Conference Coverage
12/08/2023
Stephanie Holland
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis...
12/08/2023
Oncology
FDA Approval
10/19/2026
Emily Estrada
The FDA granted accelerated approval to dostarlimab for patients with stage II/III MSI-H/dMMR locally advanced rectal cancer, establishing an immunotherapy-based treatment option supported by sustained clinical complete responses and the...
The FDA granted accelerated approval to dostarlimab for patients with stage II/III MSI-H/dMMR locally advanced rectal cancer, establishing an immunotherapy-based treatment option supported by sustained clinical complete responses and the...
The FDA granted accelerated...
10/19/2026
Oncology
FDA Approval
10/14/2026
Emily Estrada
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication...
10/14/2026
Oncology
News
10/09/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial...
10/09/2026
Oncology
News
10/08/2026
Stephanie Holland
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3...
10/08/2026
Oncology
News
10/08/2026
Emily Estrada
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study...
10/08/2026
Oncology
News
10/08/2026
Emily Estrada
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of...
10/08/2026
Oncology
News
10/08/2026
Emily Estrada
Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...
Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...
Topline results from the phase 3...
10/08/2026
Oncology
News
10/07/2026
Emily Estrada
Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...
Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...
Results from the phase 2b...
10/07/2026
Oncology
FDA Approval
10/07/2026
Stephanie Holland
Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...
Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...
Based on results from the...
10/07/2026
Oncology
FDA Approval
10/02/2026
Stephanie Holland
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN...
10/02/2026
Oncology

Quizzes

Quiz
09/25/2024
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the...
09/25/2024
Oncology
Quiz
09/25/2024
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of...
09/25/2024
Oncology
Quiz
10/08/2026
Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.
Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.
Test your knowledge of...
10/08/2026
Oncology
Quiz
06/19/2026
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated...
06/19/2026
Oncology
Quiz
06/19/2026
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory...
06/19/2026
Oncology
Quiz
06/19/2026
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a...
06/19/2026
Oncology
Quiz
06/17/2026
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in...
06/17/2026
Oncology
Quiz
06/09/2026
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA...
06/09/2026
Oncology
Quiz
06/08/2026
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase...
06/08/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
05/21/2026
Lucia Masarova, MD
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
05/21/2026
Lucia Masarova, MD
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
05/21/2026
Lucia Masarova, MD
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the...
05/21/2026
Oncology